AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36212225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness for Interdisciplinary Health Care Professionals (MIHP)
Number of subjects: 35
Study 36212504 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI of oxaliplatin plus raltitrexed (TOMOX)
Number of subjects: 113
Study 36212504 — intervention group
Group type: COMPARATOR
Intervention: HAI of oxaliplatin plus 5-fluorouracil (FOLFOX)
Number of subjects: 113
Study 36212557 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia educational and consent platform (EngagedMD-EMD)
Number of subjects: 86
Study 36212557 — intervention group
Group type: COMPARATOR
Intervention: Standard fertility counseling (conventional group)
Number of subjects: 86
Study 36212638 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based programme on relapse management
Number of subjects: 17
Study 36212652 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) combined with sound stimulation
Number of subjects: 1
Study 36212652 — intervention group
Group type: COMPARATOR
Intervention: Aricept and Sodium Oligomannate (previous treatments)
Number of subjects: 1
Study 36212980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Ty21a treatment
Number of subjects: 0
Study 36212980 — intervention group
Group type: COMPARATOR
Intervention: Standard BCG treatment
Number of subjects: 0
Study 36213913 — intervention group
Group type: EXPERIMENTAL
Intervention: Isha Kriya meditation practice, performed daily for 6 weeks.
Number of subjects: 259
Study 36214004 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000L alglucosidase alfa for 52 weeks
Number of subjects: 90
Study 36214051 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE trial (NCT00413218)
Number of subjects: 256
Study 36214051 — intervention group
Group type: EXPERIMENTAL
Intervention: APX001-201 trial (NCT03604705)
Number of subjects: 256
Study 36214051 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSTORE trial (NCT03667690)
Number of subjects: 256
Study 36214051 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall non-enrolment
Number of subjects: 256
Study 36214090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus Peg-IFN-α2b
Number of subjects: 79
Study 36214090 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib
Number of subjects: 79
Study 36214090 — intervention group
Group type: COMPARATOR
Intervention: Peg-IFN-α2b
Number of subjects: 79
Study 36214123 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Transplantation (HT) without pretransplant mechanical circulatory support (MCS)
Number of subjects: 305
Study 36214123 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Transplantation (HT) with pretransplant mechanical circulatory support (MCS)
Number of subjects: 305
Study 36214123 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term Mechanical Circulatory Support (MCS)
Number of subjects: 305
Study 36214207 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective leadership interventions
Number of subjects: 955
Study 36214278 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorders (ED) treatment
Number of subjects: 62
Study 36214278 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality disorders (PD) assessment
Number of subjects: 62
Study 36214278 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of borderline PD
Number of subjects: 62
Study 36214450 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosutured aneurysm repair (ESAR)
Number of subjects: 192
Study 36214450 — intervention group
Group type: COMPARATOR
Intervention: Standard endovascular aneurysm repair (sEVAR)
Number of subjects: 192
Study 36214614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) treatment
Number of subjects: 39
Study 36214650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Number of subjects: 576
Study 36214786 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic assay based on proximal liquid biopsy
Number of subjects: 90
Study 36214786 — intervention group
Group type: COMPARATOR
Intervention: Uterine lavage
Number of subjects: 90
Study 36214883 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 18
Study 36214883 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 18
Study 36215056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact limbs of traumatic unilateral transtibial amputees
Number of subjects: 36
Study 36215056 — intervention group
Group type: COMPARATOR
Intervention: Talar cartilage thickness
Number of subjects: 36
Study 36215056 — intervention group
Group type: COMPARATOR
Intervention: GCL muscle thickness
Number of subjects: 36
Study 36215056 — intervention group
Group type: EXPERIMENTAL
Intervention: TA and GCM muscle thicknesses
Number of subjects: 36
Study 36215065 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intense treatment for breast cancer
Number of subjects: 39
Study 36215065 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapolation of trial outcomes to underrepresented populations
Number of subjects: 39
Study 36215065 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing comfort in extrapolation
Number of subjects: 39
Study 36215115 — intervention group
Group type: EXPERIMENTAL
Intervention: Color flow Doppler ultrasound with 1 mL normal saline injection
Number of subjects: 40
Study 36215115 — intervention group
Group type: EXPERIMENTAL
Intervention: Color flow Doppler ultrasound with 1 mL air/saline mixture
Number of subjects: 40
Study 36215125 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene plus palbociclib
Number of subjects: 36
Study 36215171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 36215171 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 36215217 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib combined with vincristine, dexamethasone, asparaginase, and daunorubicin (VXLD)
Number of subjects: 24
Study 36215232 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infusion of 235 ml isotonic saline containing a technetium-99m pertechnetate tracer
Number of subjects: 6
Study 36215912 — intervention group
Group type: COMPARATOR
Intervention: Normative Improvement class
Number of subjects: 341
Study 36215912 — intervention group
Group type: EXPERIMENTAL
Intervention: High Drug Use class
Number of subjects: 341
Study 36215912 — intervention group
Group type: EXPERIMENTAL
Intervention: High Recurrence class
Number of subjects: 341
Study 36215912 — intervention group
Group type: EXPERIMENTAL
Intervention: High Criminogenic Thinking class
Number of subjects: 341
Study 36215980 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss to follow-up (LTFU)
Number of subjects: 813
Study 36215980 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete visit coverage
Number of subjects: 813
Study 36215980 — intervention group
Group type: EXPERIMENTAL
Intervention: Late visits
Number of subjects: 813
Study 36215980 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous late visits
Number of subjects: 813
Study 36215989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion
Number of subjects: 68
Study 36216013 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of BNT162b2
Number of subjects: 16994
Study 36216013 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of BNT162b2
Number of subjects: 16994
Study 36216013 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of BNT162b2 (less than 3 months after third dose)
Number of subjects: 16994
Study 36216013 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of BNT162b2 (3 months or more after third dose)
Number of subjects: 16994
Study 36216266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive endoscopic removal for downstaging of polyp burden (IDP)
Number of subjects: 222
Study 36216431 — intervention group
Group type: EXPERIMENTAL
Intervention: WeFlow-Arch modular inner branch stent-graft system
Number of subjects: 80
Study 36216842 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnl-GT-β-cell-failure
Number of subjects: 450
Study 36216842 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnl-GT-IR
Number of subjects: 450
Study 36216961 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-HIGIV
Number of subjects: 0
Study 36216961 — intervention group
Group type: COMPARATOR
Intervention: PBS (control)
Number of subjects: 0
Study 36217101 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK3486 (IV bolus dose of 0.4 mg/kg and maintenance infusion of 0.4 mg/kg/h)
Number of subjects: 24
Study 36217101 — intervention group
Group type: COMPARATOR
Intervention: HSK3486 (in subjects with mild or moderate hepatic impairment)
Number of subjects: 24
Study 36217101 — intervention group
Group type: COMPARATOR
Intervention: Normal hepatic function subjects
Number of subjects: 24
Study 36217139 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose Gam-COVID-Vac (Sputnik V)
Number of subjects: 23996
Study 36217139 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose Gam-COVID-Vac (booster)
Number of subjects: 23996
Study 36217139 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiVacCorona
Number of subjects: 23996
Study 36217139 — intervention group
Group type: EXPERIMENTAL
Intervention: CoviVac
Number of subjects: 23996
Study 36217526 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 68
Study 36217526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 36217600 — intervention group
Group type: EXPERIMENTAL
Intervention: SMBP-App
Number of subjects: 180
Study 36217600 — intervention group
Group type: COMPARATOR
Intervention: SMBP alone
Number of subjects: 180
Study 36219171 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey regarding knowledge and attitudes towards Barrett's esophagus screening
Number of subjects: 472
Study 36219171 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about developing Barrett's esophagus or esophageal adenocarcinoma
Number of subjects: 472
Study 36219171 — intervention group
Group type: COMPARATOR
Intervention: Comparison of concerns and barriers between racial groups
Number of subjects: 472
Study 36219274 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat; median average dose was 10.6 mg/day (1.1-47.9)
Number of subjects: 19
Study 36219274 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat; median exposure from baseline to study end was 5.4 years (0.04-6.7)
Number of subjects: 19
Study 36219274 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat; long-term follow-up
Number of subjects: 19
Study 36219274 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat; long-term safety profile
Number of subjects: 19
Study 36219388 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple inhaled therapy
Number of subjects: 566
Study 36219388 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting β2-agonists (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC)
Number of subjects: 566
Study 36219388 — intervention group
Group type: COMPARATOR
Intervention: Circadian rhythm of symptoms
Number of subjects: 566
Study 36219388 — intervention group
Group type: COMPARATOR
Intervention: Symptom control
Number of subjects: 566
Study 36219586 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based classifier combining multiple cellular and plasma biomarkers with clinical factors.
Number of subjects: 302
Study 36219586 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreases in regulatory natural killer cells, naïve CD4 T helper cells, and naïve regulatory T cells; elevated levels of CXCL9, CXCL10, CXCL11, ST2, ICAM-1, and soluble CD13 (sCD13).
Number of subjects: 302
Study 36219586 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD13, ST2, and ICAM-1 levels.
Number of subjects: 302
Study 36219705 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of sulfadoxine-pyrimethamine
Number of subjects: 305
Study 36219705 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of dihydroartemisinin-piperaquine (DP)
Number of subjects: 305
Study 36219705 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly DP during pregnancy
Number of subjects: 305
Study 36219705 — intervention group
Group type: EXPERIMENTAL
Intervention: DP every 3 months
Number of subjects: 305
Study 36219705 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly DP from 2 to 24 months of age
Number of subjects: 305
Study 36219705 — intervention group
Group type: EXPERIMENTAL
Intervention: More effective malaria chemoprevention
Number of subjects: 305
Study 36219705 — intervention group
Group type: COMPARATOR
Intervention: Malaria in pregnancy
Number of subjects: 305
Study 36220152 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly 300 mg marstacimab
Number of subjects: 20
Study 36220152 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly 150 mg marstacimab (after a 300 mg loading dose)
Number of subjects: 20
Study 36220152 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 20
Study 36220196 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance assessed by the insulin sensitivity index (ISI)
Number of subjects: 2752
Study 36220315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness assessment in children and adolescents with IBD
Number of subjects: 50
Study 36220315 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness components assessment (muscular strength, speed/agility, flexibility) in children and adolescents with IBD
Number of subjects: 50
Study 36220315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk assessment in adulthood based on physical fitness levels
Number of subjects: 50
Study 36220315 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and daily physical activity assessment in children and adolescents with IBD
Number of subjects: 50
Study 36220579 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional decomposition strategy
Number of subjects: 0
Study 36220579 — intervention group
Group type: EXPERIMENTAL
Intervention: Reclassifying fully mediated interaction
Number of subjects: 0
Study 36220579 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolating fully mediated interaction
Number of subjects: 0
Study 36220750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vector therapies
Number of subjects: 0
Study 36220750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial-derived delivery strategies
Number of subjects: 0
Study 36220852 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus aromatase inhibitor (AI)
Number of subjects: 2888
Study 36220852 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitor (AI) alone
Number of subjects: 2888
Study 36220881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Number of subjects: 35
Study 36221816 — intervention group
Group type: EXPERIMENTAL
Intervention: AYAC
Number of subjects: 74
Study 36221816 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 74
Study 36221952 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX chemotherapy followed by gemcitabine-based chemoradiation
Number of subjects: 22
Study 36222756 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 458
Study 36222756 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 458
Study 36222789 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenic factors classification (soluble fms-like tyrosine kinase to placental growth factor ratio ≥38)
Number of subjects: 1030
Study 36222789 — intervention group
Group type: COMPARATOR
Intervention: Standard Doppler-based management
Number of subjects: 1030
Study 36222801 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model development using biomedical and psychosocial variables collected via Noona Healthcare platform, measured every 3 months from presurgery to 18 months post-surgery.
Number of subjects: 660
Study 36222806 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive GDM prototype app with features such as automatic personalized suggestions and social support.
Number of subjects: 0
Study 36222806 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive GDM prototype app
Number of subjects: 0
Study 36222818 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives delivered through a mobile app (US $15 biweekly payments, US $2 penalties for missed check-ins)
Number of subjects: 25
Study 36222818 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives delivered through a mobile app
Number of subjects: 25
Study 36222826 — intervention group
Group type: EXPERIMENTAL
Intervention: iRaPID program (integrated rapid access to HIV prevention program)
Number of subjects: 50
Study 36222826 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 50
Study 36222855 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVmax-FAPI
Number of subjects: 34
Study 36222855 — intervention group
Group type: EXPERIMENTAL
Intervention: GTV
Number of subjects: 34
Study 36223060 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 0.005% plus Betamethasone Dipropionate 0.064% (Cal/BD) foam
Number of subjects: 0
Study 36223060 — intervention group
Group type: COMPARATOR
Intervention: Halobetasol Proprionate 0.01% plus Tazarotene 0.045% (HP/Taz) lotion
Number of subjects: 0
Study 36223197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0
Study 36223197 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 36223228 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM-Beta spike vaccine
Number of subjects: 0
Study 36223228 — intervention group
Group type: COMPARATOR
Intervention: ACM-WT spike vaccine
Number of subjects: 0
Study 36223228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) immunization
Number of subjects: 0
Study 36223228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) immunization
Number of subjects: 0
Study 36223228 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM-polymersome-based Covid-19 vaccine
Number of subjects: 0
Study 36223234 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus infection (GII)
Number of subjects: 158
Study 36223234 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic norovirus infection
Number of subjects: 158
Study 36223234 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization for symptomatic episodes
Number of subjects: 158
Study 36223234 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial infections vs subsequent infections
Number of subjects: 158
Study 36223547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinengotinib (TT-00420)
Number of subjects: 0
Study 36223558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 36223558 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 36223740 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitor olaparib
Number of subjects: 0
Study 36223740 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CD47 antibodies and olaparib
Number of subjects: 0
Study 36223780 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging pre-processing
Number of subjects: 0
Study 36223780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-processing)
Number of subjects: 0
Study 36223961 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) - single intravenous infusion of 375 mg/m²
Number of subjects: 44
Study 36223961 — intervention group
Group type: COMPARATOR
Intervention: Standardised corticosteroid treatment
Number of subjects: 44
Study 36224176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, trastuzumab, and doublet chemotherapy
Number of subjects: 43
Study 36224398 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic manoeuvres (six neck manoeuvres: flexion, extension, lateroflexion left/right, traction and compression; three jaw manoeuvres: protrusion, laterotrusion left/right; one placebo manoeuvre: hand on head)
Number of subjects: 18
Study 36224595 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost nonlinear regression prediction model
Number of subjects: 249
Study 36225250 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 84
Study 36225250 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 84
Study 36225342 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTE-MINOCA
Number of subjects: 110
Study 36225342 — intervention group
Group type: COMPARATOR
Intervention: NSTE-MI-CAD
Number of subjects: 110
Study 36225538 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity levels
Number of subjects: 500
Study 36225538 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometrics, fasting blood samples, non-blood biomarkers, 24-hour food recall
Number of subjects: 500
Study 36226495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivavotinib (TAK-659) 140 mg QD
Number of subjects: 43
Study 36226495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivavotinib (TAK-659) 60 mg BID
Number of subjects: 43
Study 36226495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivavotinib (TAK-659)
Number of subjects: 43
Study 36227183 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolocate (Renishaw)
Number of subjects: 23
Study 36227203 — intervention group
Group type: EXPERIMENTAL
Intervention: n-of-1 trials using ambulatory BP monitoring
Number of subjects: 49
Study 36227203 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 49
Study 36227531 — intervention group
Group type: EXPERIMENTAL
Intervention: PROFAD-SSI-SF
Number of subjects: 46
Study 36227606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cell transgene RS1 expression using MiniPromoter (Ple155)
Number of subjects: 0
Study 36227606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cell transgene RS1 expression using mini-mGluR6 promoter
Number of subjects: 0
Study 36227606 — intervention group
Group type: COMPARATOR
Intervention: Control (no RS1 expression)
Number of subjects: 0
Study 36227718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP control (goal SBP <120 mm Hg)
Number of subjects: 1430
Study 36227718 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP control (goal SBP <140 mm Hg)
Number of subjects: 1430